Most interesting to me this week, a paper just published in The Lancet Psychiatry suggested that MDMA-assisted psychotherapy were effective and well-tolerated in reducing PTSD symptoms in veterans and first responders. The New York Times covered it here. This drug has shown a lot of promise in the treatment of PTSD: the FDA granted MDMA-assisted psychotherapy breakthrough therapy designation (which could expedite approval), and a Phase 3 clinical trial is in motion.
Another interesting read is the “zero LDL-cholesterol hypothesis” paper (it’s behind a paywall) recently published in the Journal of Clinical Lipidology. I hope to dig into this one in more detail soon…maybe on the podcast with a lipidology expert.